A Systematic Review and Meta-analysis of Psychosocial Interventions to Reduce Drug and Sexual Blood Borne Virus Risk Behaviours Among People Who Inject Drugs by Gilchrist, Gail et al.
This is an author produced version of A Systematic Review and Meta-analysis of 
Psychosocial Interventions to Reduce Drug and Sexual Blood Borne Virus Risk 
Behaviours Among People Who Inject Drugs.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/114992/
Article:
Gilchrist, Gail, Swan, Davina, Widyaratna, Kideshini et al. (5 more authors) (2017) A 
Systematic Review and Meta-analysis of Psychosocial Interventions to Reduce Drug and 
Sexual Blood Borne Virus Risk Behaviours Among People Who Inject Drugs. AIDS and 
behavior. ISSN 1573-3254 
https://doi.org/10.1007/s10461-017-1755-0
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
SUBSTANTIVE REVIEW
A Systematic Review and Meta-analysis of Psychosocial
Interventions to Reduce Drug and Sexual Blood Borne Virus Risk
Behaviours Among People Who Inject Drugs
Gail Gilchrist1,2 • Davina Swan1 • Kideshini Widyaratna1 • Julia Elena Marquez-Arrico3 •
Elizabeth Hughes4 • Noreen Dadirai Mdege5 • Marrissa Martyn-St James6 •
Judit Tirado-Munoz7
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract Opiate substitution treatment and needle
exchanges have reduced blood borne virus (BBV) trans-
mission among people who inject drugs (PWID). Psy-
chosocial interventions could further prevent BBV. A
systematic review and meta-analysis examined whether
psychosocial interventions (e.g. CBT, skills training) com-
pared to control interventions reduced BBV risk behaviours
among PWID. 32 and 24 randomized control trials (2000-
May 2015 in MEDLINE, PsycINFO, CINAHL, Cochrane
Collaboration and Clinical trials, with an update in MED-
LINE to December 2016) were included in the review and
meta-analysis respectively. Psychosocial interventions
appear to reduce: sharing of needles/syringes compared to
education/information (SMD -0.52; 95% CI -1.02 to
-0.03; I2 = 10%; p = 0.04) or HIV testing/counselling
(SMD-0.24; 95%CI-0.44 to-0.03; I2 = 0%; p = 0.02);
sharing of other injecting paraphernalia (SMD -0.24; 95%
CI-0.42 to-0.06; I2 = 0%; p\ 0.01) and unprotected sex
(SMD-0.44; 95%CI-0.86 to-0.01; I2 = 79%; p = 0.04)
compared to interventions of a lesser time/intensity, how-
ever, moderate to high heterogeneity was reported. Such
interventions could be included with other harm reduction
approaches to prevent BBV transmission among PWID.
Resumen El tratamiento de sustitucio´n de opia´ceos y los
programas de intercambio de jeringuillas han disminuido
la transmisio´n de virus transmitidos por sangre (VTS) entre
los usuarios de drogas inyectadas (UDI). Las intervencio-
nes psicosociales podrı´an prevenir la transmisio´n de VTS.
Mediante una revisio´n sistema´tica con meta-ana´lisis, se
estudio´ si las intervenciones psicosociales (p.e. CBT,
entrenamiento en habilidades) redujeron los comporta-
mientos de riesgo asociados a los VTS entre UDI, en
comparacio´n con las intervenciones control. Se incluyeron
32 y 24 ensayos clı´nicos aleatorizados en la revisio´n y
meta-ana´lisis, respectivamente (2000-mayo 2015 en
MEDLINE, PsycINFO, CINAHL, Colaboracio´n Cochrane
y Clinical Trials, con una actualizacio´n en MEDLINE
hasta diciembre de 2016). Las intervenciones psicosociales
disminuyen los siguientes comportamientos de riesgo:
compartir agujas/jeringuillas en comparacio´n con la edu-
cacio´n/informacio´n (DME -0.52; IC del 95%: -1.02,
-0.03; I2 = 10%; p = 0.04) o en comparacio´n con ase-
soramiento/pruebas para el VIH (DME -0.24; IC del 95%:
-0.44, -0.03; I2 = 0%, p = 0.02); compartir otros
utensilios de inyeccio´n (DME -0.24; IC del 95%: -0.42,
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Table 1 Description of trials included in the systematic review and meta-analyses
Authors Participants
(% female)
Intervention delivery
setting/staff
Intervention group description Control group description Length of
follow-up
Intervention group/s Number of
sessions
Intervention
function/s
Control intervention Number of
sessions
Abou-Saleh et al.
[31]
95 HCV-ve
PWID (26%)
Outpatient drug treatment/
treatment staff
Enhanced prevention counselling
(N = 43)
4 9 40–60 min
sessions
Education,
enablement
Simple educational
counselling (N = 52)
1 9 10 min session 6 months post
randomisation
Avants et al. [32] 220 PWID in
methadone
maintenance
treatment
(MMT) (69%)
MMT/clinician Standard care ? harm reduction group
(N = 108)
12 9 90 min
weekly group
sessions
Education,
enablement,
training
Standard care ? single
HIV risk reduction
session (N = 112)
1 9 2 h session Post intervention
Bertrand et al. [33] 219 PWID that
shared drugs or
injection
equipment
(18%)
Not specified/researcher Motivational intervention (MI)
(N = 111)
1 session Enablement,
persuasion
Education Intervention
(N = 108)
1 9 30–45 min 6 months post
randomisation
Booth et al. [17] 632 PWID (24%) Residential detoxification/
interventionist
Treatment as usual (TAU) ? HIV/HCV
counselling and education (C&E)
(N = 212)
TAU ? intervention to facilitate
treatment entry (N = 209)
2 individual
sessions
individual
session
Education,
enablement,
training
TAU: HIV/HCV risk
assessment screening
and referral for testing
and counselling
(N = 211)
HIV/HCV risk
assessment
screening and
referral for testing
and counselling
6 months post
randomisation
Dushay et al. [34] 669 drug users
[64% injecting]
(27%)
Not reported Ethnic cultural enhanced intervention
(n = 453)
5 sessions Education,
enablement,
training
AIDS video educational
programme (N = 216)
2 video sessions 5–10 months post
randomisation (20%
interviewed
12 months post
randomisation)
El-Bassell et al. [35] 282 HIV-
negative drug-
using couples
(16% PWID)
(50%)
Not reported/trained
facilitator
Couple-based risk reduction (n = 190)
Individual-based HIV risk reduction
delivered to male or female drug using
partner (n = 183)
7 sessions Enablement,
training
Couple-based wellness
promotion (n = 190)
7 sessions 12 months post
randomisation
Gagnon et al. [37] 260 PWID (31%) Needle
exchange/computerised
intervention
Standard intervention (needle
exchanges, psychosocial support and
social and health service
referrals) ? computer-tailored
messages (N = 130)
4 sessions Education,
enablement,
modelling,
persuasion
standard intervention
(N = 130)
4 weeks 3 months post
intervention
Garfein et al. [38],
Purcell et al. [47],
Mackesy-Amiti
et al. [42, 60, 61]
654 HIV-ve and
HCV-ve PWID
(34%)
Not reported/trained
facilitators
Peer education (N = 431) 6 sessions Education,
enablement,
training
Video discussion
(N = 423)
6 sessions 6 months post
intervention
A
ID
S
B
eh
av
1
23
Table 1 continued
Authors Participants
(% female)
Intervention delivery
setting/staff
Intervention group description Control group description Length of
follow-up
Intervention group/s Number of sessions Intervention
function/s
Control intervention Number of
sessions
Gilbert et al.
[22]
40 HIV-ve
couples who
inject drugs
(50%)
Needle exchange/facilitators Couple based HIV risk reduction (20
couples)
3 single-gender group
sessions ? couple
session
Education,
modelling,
training
Wellness promotion condition
(20 couples)
4 group sessions 3 months post
intervention
Go et al. [59] 419 index HIV-
ve PWID
(0%)
Not reported Peer network-oriented (N = 210) 6 sessions ? 3 booster
sessions
Education,
enablement,
training
TAU ? HIV pamphlet
(N = 209)
n/a 12 months post
intervention
Go et al. [30] 455 HIV ? ve
PWID (0%)
Community intervention
education sessions
delivered by a trained
community mobilizer;
Individual HIV knowledge
and skill-building group
sessions conducted by two
facilitators
Individual level
HIV testing and counselling, plus 2
individual post-test counselling
sessions, 2 small group sessions
(HIV knowledge and skill-
building) ? optional dyad session
(N = 95)
Community and individual level
Community-wide programme
consisting of a 2-part video and a
series of 6 HIV education sessions
(N = 132)
4 individual
sessions ? 2 group
sessions ? optional
dyad session
2-part video and a
series of 6 HIV
education sessions
Education,
enablement,
training
education
Individual level
HIV testing and counselling
(N = 89)
Community level
Standard messages on HIV
through village weekly public
loudspeakers and educational
pamphlets already being
provided by community
health stations (N = 139)
2 sessions 24 months post
randomisation
Hoffman [23] 432 PWID
(33%)
Research centre/facilitators Psychological-communicative
behavioral training
Peer educator (N = 99)
Network members (N = 127)
7 group ? 1
individual
session ? 4 booster
meetings
Education,
modelling,
persuasion,
training
Group sessions devoted to areas
of interest (N = 92)
Network members (N = 114)
8 sessions 24 months post
randomisation
Latka et al.
[41],
Kapadia
et al. [58]
418 HCV ? ve
PWID (24%)
3 research sites/facilitators Peer-mentoring behavioural
intervention (N = 222)
6 sessions Education,
training
Video-discussion (N = 196) 6 sessions 6 months post
intervention
Latkin et al.
[21]
250 [47%
PWID]
(39%)
Clinic/indigenous para-
professional facilitators
Small-group which encouraged peer
outreach (N = 81)
10 group sessions Enablement,
education,
training
Equal-attention control
condition (N = 36)
10 sessions 6 months post
intervention
Latkin et al.
[18, 57]
414 networks
with 1123
HIV-ve
participants
[91% PWID
(3% in
Thailand;
20% in US)
Not reported/facilitator HIV counselling and testing
(C&T) ? group peer-education
(N = 204 networks)
2 individual ? 6
group ? 2 booster
sessions
Education,
enablement,
persuasion,
training
HIV C&T (N = 210 networks) 2 sessions Up to 30 months
(24 in
Thailand) post
randomisation
Margolin et al.
[43]
90 PWID
HIV ? ve
entering
MMT (30%)
MMT/counsellor Enhanced-MMT (E-MMP) (6 months
of daily methadone and weekly
individual substance abuse
counseling and case
management) ? HIV Harm
Reduction Program (N = 45)
6-sessions Enablement,
persuasion,
training
Enhanced-MMT (E-
MMP) ? active control that
included harm reduction
components (N = 45)
6 sessions 9 months post
randomisation
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Table 1 continued
Authors Participants
(% female)
Intervention delivery
setting/staff
Intervention group description Control group description Length of
follow-up
Intervention group/s Number of sessions Intervention
function/s
Control intervention Number of
sessions
McMahon
et al.
[44, 45]
330 HIV-ve
drug users
[48% PWID]
(100%) and
male partners
Field office/interventionist (1) Couple-Based HIV C&T
(N = 110) [43% PWID]
(2) Women only relationship-focused
HIV C&T (N = 104) [51% PWID]
2 sessions
2 sessions
Education,
enablement
HIV C&T (N = 116) [51%
PWID]
2 sessions 9 months post
intervention
Otiashvili et al.
[46]
40 drug users
[98% PWID]
(0%) and
drug-free
female
partners
Research unit/counsellor MI for drug user and couple,
contingency
management ? naltrexone
(n = 20). Female partners invited
to attend couples counselling
22 sessions Enablement,
incentivisation
Education sessions. Referrals
drug treatment (n = 20)
22 sessions 6 months post
intervention
Purcell et al.
[47, 56]
966 HIV ?ve
PWID (36%)
Not reported/peers Peer mentoring intervention
(N = 486)
10 sessions (7 group; 2
individual; 1 ‘peer
activity’)
Education,
enablement,
training
Video discussion (N = 480) 8 sessions 12 months post
intervention
Robles et al.
[48]
557 PWID
(4%)
Assessment facility or drug
treatment/nurse
HIV/AIDS risk
intervention ? counselling ? case
management (N = 285)
2 sessions
6 sessions
Education,
Enablement,
training
HIV/AIDS risk intervention
(N = 272)
2 sessions 6 months post
randomisation
Rotheram-
Borus et al.
[49] and
Hershberger
et al. [40]
1116 drug users
[65% PWID]
(33%)
Field office/counsellors/
outreach workers
HIV C&T ? HIV prevention
programme (group skills focused
workshops, individual counselling,
outreach/social events)
(N = 558; 359 PWID)
2 HIV C&T
sessions ? 5
sessions (2 group, 1
individual ?C2
structured outreach)
Enablement,
training
HIV C&T (N = 559; 364
PWID)
2 sessions 9 months post
randomisation
Samet et al.
[50]
700 HIV ? ve
with risky
sex and
heavy
alcohol
consumption
[60% PWID]
(41%)
Hospital setting/peers Healthy relationships intervention
(n = 350; 212 PWID)
2 individual ? 3 small
group sessions
Education,
enablement,
modelling,
training
Attention control (n = 350; 211
PWID)
2 individual ? 3
group sessions
12 months post
randomisation
Schroeder
et al. [20]
and Epstein
et al. [36]
81 drug users
[96% PWID]
(52%)
Research clinic/counsellor MMT ? individual counselling
followed by 12 weeks of
intervention condition, followed by
a 12-week standard treatment
(1) weekly CBT ? contingent
vouchers (CM) (N = 16)
(2) weekly CBT ? noncontingent
vouchers (N = 19)
(3) CM plus weekly group therapy
(N = 22)
29 weeks
(methadone ? 5
weekly individual
counselling,
12 weeks of
intervention,
followed by
12 weeks standard
treatment
Education,
Enablement,
Incentivisation
Modelling,
training
Standard dose of methadone
(70–80 mg/day) ? ? weekly
individual counselling
(5 weeks) followed by
12 weeks of control condition,
followed by a 12-week
standard treatment
Group therapy ? non-
contingent vouchers (N = 24)
29 weeks
(methadone ? 5
weekly individual
counselling,
12 weeks of
intervention,
followed by
12 weeks
standard
treatment
Post intervention
Stein et al. [51] 109 PWID who
drink
hazardously
(38%)
Research site/social worker Referrals for substance use and
medical treatment ? brief MI
(N = 60)
2 sessions Enablement Referrals for substance abuse
and medical treatment
provided (N = 49)
n/a 6 months post
randomisation A
ID
S
B
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Table 1 continued
Authors Participants
(% female)
Intervention delivery
setting/staff
Intervention group description Control group description Length of
follow-up
Intervention group/s Number of sessions Intervention
function/s
Control intervention Number of
sessions
Stein et al. [52] 109 PWID
(36%)
Outpatient academic
research office/Clinical
Psychologist
CBT ? pharmacotherapy for
depression (N = 53)
8 CBT sessions ? 3
pharmacotherapy
visits
Education,
Enablement,
Training
Assessment (N = 56) Assessment visit 9 months post
randomisation
Stein et al. [53] 277 HCV-ve
drug users
[28% PWID]
(37%)
Not stated/interventionist MI (N = 140) 4 sessions Education,
enablement,
persuasion
Leaflet about local resources
(N = 137)
n/a 24 months post
randomisation
Sterk et al.
[29]
68 HIV-ve
PWID
(100%)
Health intervention project
house/interventionists
Enhanced MI (EMI) (N = 20)
Enhanced negotiation intervention
(ENI) (N = 21)
4 sessions
4 sessions
Education,
enablement,
training
NIDA standard intervention
(N = 27)
2 sessions 6-months (not
clear if post
intervention or
post
randomisation)
Strathdee et al.
[26] and
Vera et al.
[55]
584 Sex
workers who
inject drugs
(100%)
Not reported/counsellors Interactive injection risk and didactic
sexual risk intervention (N = 146)
Interactive sexual risk and didactic
injection risk intervention
(N = 148)
Interactive Injection and Sexual Risk
Intervention) (N = 146)
1 session
1 session
1 session
Education,
enablement,
modelling,
persuasion,
training
Didactic injection and sexual
risk intervention (N = 144)
1 9 60 min session 12 months post
randomisation
Tobin et al.
[25]
227 PWID
(45%)
Research clinic/not reported Peer educator intervention (N = 114) 7 sessions (5
group ? 1
individual ? 1 with
participant and
enrolled Risk
Network Members)
Education,
enablement,
training
Group information (N = 113) 5 sessions 18 months post
intervention
Tucker et al.
[54]
145 PWID
(26%)
Out-patient clinical and
research
organization/clinical
researcher
Tailored brief behavioural
intervention (N = 73)
1 session Education,
enablement
HCV educational leaflet
(N = 72)
n/a 1 month post
randomisation
Wechsberg
et al. [24]
100 PWID
(100%)
Inpatient detoxification/
psychologist
Woman-focused Intervention
(N = 51)
2 sessions Education,
enablement,
training
Nutrition intervention (N = 49) 2 sessions 3 months post
randomisation
Zule et al. [19] 851 PWID
(27%)
Not reported/lay community
members
HCV risk reduction MI (n = 423) 6 sessions Education,
enablement,
modelling,
persuasion
Video HCV educational
intervention (n = 428)
6 sessions 12 months post
randomisation
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-0.06; I2 = 0%; p\ 0.01) y el sexo sin proteccio´n (DME
-0.44; IC del 95%: -0.86, -0.01; I2 = 79%; p = 0.04) en
comparacio´n con las intervenciones de menor duracio´n/
intensidad. Sin embargo, se ha detectado una heteroge-
neidad de moderada a alta. Tales intervenciones podrı´an
incluirse junto con otros enfoques de reduccio´n de dan˜os
para prevenir la transmisio´n de VTS entre los UDI.
Keywords People who inject drugs  Psychosocial
intervention  Blood borne virus  Injecting risk behaviour 
Sexual risk behaviour  Systematic review  Meta-analysis
Introduction
Among people who inject drugs (PWID), prevalence of the
Hepatitis C virus (HCV) and HIV is around 5–90% [1] and
\1–50% [2] respectively. While pre-exposure prophylaxis
for HIV [3] and treatment for HCV are effective [4], no
vaccine prevents HCV. Opiate substitution therapy (OST)
and needle exchanges effectively reduce HIV and HCV
among PWID [5]. Psychosocial interventions (e.g. moti-
vational interviewing, cognitive behavioural therapy and
contingency management) could further decrease blood
borne viruses (BBV) by educating PWID about transmis-
sion risks and developing strategies to avoid them.
Several systematic reviews and meta-analyses of psy-
chosocial interventions to reduce BBV risk behaviours
among drug users have reported modest effects [6–9].
Reviews conclude that harm reduction interventions,
especially OST and needle exchange programmes, have
reduced injecting risk behaviours, but have not prevented
HCV transmission among PWID [5]. In addition, combined
substance-use treatment and support for safe injection were
most effective in reducing HCV seroconversion among
PWID [6]. Interventions that target capability (i.e. indi-
vidual’s psychological and physical capacity to engage in
the activity concerned including having the necessary
knowledge and skills), opportunity (i.e. factors outside the
individual that make the behaviour possible or prompt it),
and motivation are thought to be more effective in
addressing behaviour change than interventions that
address one or fewer of these components [10]. In partial
support of this, two reviews concluded that multi-session
psychosocial interventions compared to educational inter-
ventions had minimal benefits on injecting risk behaviours
[7] and modest benefits on sexual risk behaviours among
people who use drugs [8]. In addition, large positive effects
were reported compared to minimal interventions for
reducing HIV sexual risk behaviours [8]. Despite these
promising findings, another review concluded that beha-
vioural interventions (peer-intervention training and coun-
selling interventions) were ‘‘unlikely … [to] have a
considerable effect on HCV transmission’’ for PWID (p.
176) [9].
PWID are more likely to have BBV than people who use
drugs but do not inject [11]. Alongside elevated risks from
sharing injecting equipment, some PWID report greater
high-risk sexual behaviours, including sex trading, multiple
sex partners and sex without a condom, than people who
use drugs but do not inject [11–14].
Objective
This systematic review and meta-analysis sought to
examine whether psychosocial interventions could reduce
injecting and sexual risk behaviours compared to usual
care; education or information; HIV testing and coun-
selling; or interventions of lesser time or intensity (with
and without OST).
Methods
A systematic review with meta-analysis was conducted in
accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses [15] and registered
with the International Prospective Register of Systematic
Reviews (PROSPERO 014:CRD42014012969).
Search Strategy
The search strategy is described in Table I of the Supple-
mentary Online document. The following databases were
searched for relevant randomised controlled trials (RCTs)
published from 2000 until 26 May 2015: MEDLINE,
PsycINFO, CINAHL and the Cochrane Collaboration, with
an update search in MEDLINE to 9 December 2016.
Additionally, Clinical Trials databases were searched to
identify additional publications. Forward and backward
searching of references was conducted and reference lists
of recent relevant reviews were cross-checked to verify all
relevant RCTs were included in the current systematic
review.
Eligibility
Citations were included if full text was published in Eng-
lish. Studies were eligible if (1) published during
2000–2016; (2) participants were PWID or results pre-
sented for PWID; (3) they were RCTs; (4) outcome/s
included: (i) any injecting risk behaviour including sharing
of needle/syringes or other injecting paraphernalia, and
injecting frequency, reported separately or as an aggregated
outcome, (ii) any sexual risk behaviour including unpro-
tected sex or number of sexual partners, reported separately
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or as an aggregated outcome; and (5) psychosocial inter-
ventions were compared to a control group, who received
usual care, education or information, HIV testing and
counselling, ‘‘an intervention of lesser time or intensity’’
[9] (with and without OST).
GG and NM independently assessed all abstracts and
potentially eligible full-text manuscripts against eligibility
criteria. Where disagreement regarding study inclusion
occurred, decisions were reached through referral to addi-
tional reviewers, EH, DS, KW.
Data Extraction
DS, KW, JM, and GG extracted the following data on each
study using a checklist: authors, publication year, country,
aim of intervention, participants (% PWID, % females, and
mean age), intervention delivery setting/staff, intervention
description, adherence, description of control interventions,
follow-up duration and results (Table 1). These data were
verified by a second reviewer and differences resolved
through discussion.
Methodological Quality
Two authors (from GG, DS, JM, JT) independently
assessed the trial’s methodological quality across six
domains using the Cochrane Risk of Bias tool [16]:
sequence generation; allocation concealment; blinding of
participants, personnel, and outcome assessors; incomplete
outcome data; selective outcome reporting; and other
sources of bias (Fig. 2). Assessments were compared to
quality assessments from published reviews [5–7, 9], and
differences resolved through discussion with a third
assessor, EH.
Intervention Descriptions
Intervention functions were categorised using The Beha-
viour Change Wheel [10], including: education (increasing
knowledge/understanding), e.g. ‘‘The 30 min pre-test
counseling session provided basic information about…how
to reduce the risk of HIV’’ [17], persuasion (using com-
munication to induce positive/negative feelings/stimulate
action) e.g. ‘‘facilitators…praise[d] their effective com-
munication strategies’’ [18] and ‘‘reaffirmed commitment
to change’’ [19], incentivisation (creating expectation of
reward), e.g. ‘‘Contingent vouchers were given when a
participant provided a cocaine-negative urine specimen’’
[20], training (imparting skills), e.g. ‘‘skills building to
teach personal risk reduction and negotiation’’ [21] and
‘‘technical condom use and syringe disinfection skills’’
[22], modelling (providing example/s for people to aspire
to/imitate), e.g. ‘‘model injection and sexual risk reduction
behaviors with their risk network members’’ [23] and
‘‘demonstration and rehearsal of syringe cleaning’’ [19],
and enablement (increasing means/reducing barriers) e.g.
‘‘women created a personalized risk-reduction plan’’ [24],
‘‘goal-setting for HIV risk reduction’’ [25] and role play
‘‘to help identify barriers to safer injection’’ [26] (Table 1).
Functions that related directly to the intervention’s target
behaviour/s were coded. GG and DS independently deter-
mined intervention functions. Disagreements were resolved
through discussion. Intervention functions assigned to five
trials were validated by a behaviour change expert.
Statistical Analysis
The principal summary measure was the standardized
mean difference (SMD). As outcome data were presented
as dichotomous or continuous data across included RCTs,
odds ratios (OR) were recalculated as SMD to allow data
pooling. The standard errors of log OR were converted to
standard errors of a SMD by multiplying by the same
constant (H3/p = 0.5513). This allowed the standard error
for the log OR and hence a confidence interval (CI) to be
calculated. For each RCT, the SMD and corresponding
95% CIs for the assessed outcome were retrieved or cal-
culated [27]. Data entry and statistical analysis were per-
formed using Review Manager Software. Where RCTs
reported data from various follow-up periods, data from the
latest follow-up period were included in the meta-analysis,
combining outcomes assessed at multiple time periods. To
determine whether RCTs included in the meta-analysis
were consistent, the degree of heterogeneity was calcu-
lated. I2 of 25% was considered low, 50% moderate and
75% high heterogeneity [28]. In the inverse variance
method, individual effect sizes were weighted according to
the reciprocal of their variance calculated as the square of
the standard error.
Main and Subgroup Analysis
In line with a recent Cochrane review [7] and in an attempt
to address the complexity of clinical heterogeneity of
interventions, sub-group analyses were conducted to com-
pare psychosocial interventions with (1) treatment as usual;
(2) education or information; (3) HIV testing and coun-
selling; and (4) control interventions of lesser time or
intensity with and (5) without OST. As follow-up duration
may affect intervention effectiveness, further sub-group
analyses were conducted where possible, comparing length
of time in months from the end of the intervention to the
final follow-up of included trials (i.e. B3, 4–6, and
C9 months follow-up).
Where RCTs included in the meta-analyses had more
than one intervention group [17, 20, 29], data from the
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psychosocial intervention most relevant to the aims of this
systematic review were compared to the control interven-
tion. For Booth et al. [17], the most relevant intervention
condition was considered treatment as usual (TAU) ? -
HIV/HCV counselling and education (C&E), rather than
TAU ? a therapeutic alliance to facilitate treatment entry.
For Sterk et al. [29], the enhanced negotiation intervention
(ENI) was considered more relevant than the enhanced
motivation intervention (EMI). For Schroder et al. [20],
TAU? weekly CBT ? contingent vouchers (CM)
(CBT ? CM) was considered superior to both weekly
CBT ? noncontingent vouchers and CM ? weekly group
therapy, and therefore selected as the intervention condi-
tion for the meta-analysis. Go et al. [30] conducted a multi-
level intervention using a 2 9 2 (four-arm) factorial design
consisting of: (1) standard of care (i.e. HIV testing and
counselling); (2) structural-level community stigma
reduction programme; (3) individual-level post-test coun-
selling and skill-building support groups; (4) both indi-
vidual and structural level activities. For the purpose of this
systematic review, the individual-level post-test coun-
selling and skill-building support groups will be compared
to individual standard of care.
Random effect models were applied to compare the fol-
lowingoutcomesof interest formeta-analysis by typeof control
intervention, and by type of control intervention and length of
follow-up post intervention: any injecting risk behaviour
(Fig. 3a; Table 2) including sharing of needle/syringes
(Fig. 3b; Table 2) or other injecting paraphernalia (Fig. 3c;
Table 2), and frequency of injecting (Fig. 3d; Table 2),
reported separately or as an aggregated outcome; and any
sexual risk behaviour (Fig. 4a; Table 3) including unprotected
sex (Fig. 4b; Table 3) or number of sexual partners (Fig. 4c;
Table 3), reported separately or as an aggregated outcome.
Results
Study Selection
Database searches to 26May 2015 resulted in 2493 citations;
an additional 77 citations were identified from 1 January
2015 to 9 December 2016 (Fig. 1). One additional manu-
script was identified from hand-searching other reviews’
reference lists. After removal of duplicates, 1903 citations
remained. In total, 1771 abstracts were excluded as they did
not meet eligibility criteria and 132 abstracts were selected
for full-text assessment, including four related manuscripts
referenced in these selected texts. Eighty-nine articles were
excluded as: they were not RCTs (n = 34); outcomes of
interest were not assessed/presented (n = 29); outcomes
were not presented by PWID (n = 6); number of PWID was
not reported (n = 4); or the intervention was not
psychosocial (n = 4). Additionally, ten manuscripts were
excluded as intervention group outcomeswere not compared
or did not evaluate the intervention’s effect. One further
manuscript was excluded because both treatment arms
received the same psychosocial intervention; the interven-
tion arm received a 90-day free OST coupon. One manu-
script published in Chinese was excluded [a full list of
excluded references available on request].
Forty-two manuscripts from 32 RCTs were eligible
[17–26, 29–55]. The meta-analyses included 24 trials
[17–22, 24, 25, 29–31, 33, 38, 39, 41, 43, 46–52, 54]. Eight
trials were excluded from the meta-analysis for: not pro-
viding the number of PWID for control and intervention
groups at follow-up [32, 34, 35, 45, 53], only providing risk
ratios [37], outcome combined HIV with sexually trans-
mitted infections [26] and data for ‘unsafe injection prac-
tices’ was only presented at baseline [23].
Quality Assessment
Risk of bias varied across RCTs (Fig. 2). Incomplete outcome
data was the most common risk of bias, but selective outcome
reporting contributed to risk of bias for some trials. Other
potential sources included altering randomisation protocols
depending on number of participants enrolled on a particular
day [41], significant baseline differences between groups in
outcomeof interest [31], variation in theTAUgroupacross sites
[17]; possible cross-over contamination between groups
[18, 24, 38, 39, 41, 50], a high proportion of excluded indi-
viduals who differed significantly to those included [20], and
large variations reported in follow-up period [23].
Study Characteristics
Characteristics of included RCTs are described in Table 1
(and more detail is presented in the Online Supplementary
document Table II). In total, 12,840 participants (35%
female; range 0–100%) were enrolled; the majority were
PWID (84.5%) (range 16–100%). Most trials (n = 18)
were conducted in the US [17, 19–21, 25, 29, 32, 34, 35,
38, 41, 43, 45, 47, 49, 51–53]; three in Russia [23, 24, 50];
two in Canada [33, 37]; two in Vietnam [30, 39]; and one
in Kazakhstan [22]; Georgia [46]; Australia [54]; the UK
[31]; Mexico [26]; and Puerto Rico [48]. One trial was
conducted in both the US and Thailand [18].
Trials included in the systematic review compared
psychosocial interventions with usual care (n = 4)
[17, 37, 51, 52], education or information (n = 9)
[19, 25, 26, 33, 34, 39, 46, 53, 54], HIV testing and
counselling (n = 5) [18, 30, 45, 48, 49], interventions of
lesser time or intensity with (n = 12)
[21–23, 29, 31, 32, 35, 38, 41, 47, 50] and without OST
(n = 2) [20, 43].
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Table 2 Injecting risk behaviours by control intervention and length of follow-up post-intervention
Outcome N
studies
N
participants
Std. mean difference (IV to random to
95 CI)
p value for
effect
I2
(%)
Any injecting risk behaviours by control intervention and length of follow-up post-intervention
Subgroups
Usual care (4–6 months) 3 641 -0.09 (-0.32 to 0.15) 0.48 26%
Education/information (B3 months) 1 145 0.00 (-0.35 to 0.36) 0.98 N/A
Education/information (6 months) 2 259 -0.78 (-1.61 to 0.05) 0.07 73%
Education/information (C9 months) 2 646 -0.41 (-0.74 to -0.08) 0.01 0%
HIV testing and counselling (6 months) 1 557 -0.47 (-0.94 to -0.00) 0.05 N/A
HIV testing and counselling (C9 months) 2 588 -0.18 (-0.40 to 0.04) 0.11 0%
Intervention lesser frequency or intensity without OST (C9 months) 2 1389 0.00 (-0.24 to 0.25) 0.98 31%
Intervention lesser frequency or intensity without OST (B3 months) 2 180 -0.79 (-1.56 to -0.02) 0.04 83%
Intervention lesser frequency or intensity without OST (6 months) 5 1532 -0.32 (-0.55 to -0.10) 0.004 55%
Intervention lesser frequency or intensity with OST (B3 months) 1 40 0.66 (-0.72 to 2.03) 0.35 N/A
Intervention lesser frequency or intensity with OST (C9 months) 1 90 0.06 (-0.82 to 0.93) 0.9 N/A
Any injecting risk behaviours by control intervention and length of follow-up post-intervention
(overall)
22 6067 -0.29 (-0.42 to -0.15) \0.0001 61%
Sharing needles/syringes by control intervention and length of follow-up post-intervention
Subgroups
Usual care (4–6 months) 1 109 -0.53 (-1.12 to 0.07) 0.08 N/A
Education/information (4–6 months) 2 259 -0.57 (-1.30 to 0.16) 0.12 44%
Education/information (C9 months) 1 419 -0.24 (-1.23 to 0.76) 0.64 N/A
HIV testing and counselling (4–6 months) 1 557 -0.47 (-0.94 to -0.00) 0.05 N/A
HIV testing and counselling (C9 months) 2 588 -0.18 (-0.40 to 0.04) 0.11 0%
Intervention lesser frequency or intensity without OST (C9 months) 1 423 0.11 (-0.15 to 0.37) 0.4 N/A
Intervention lesser frequency or intensity without OST (B3 months) 1 80 -1.19 (-1.67 to -0.72) \0.00001 N/A
Intervention lesser frequency or intensity without OST (4–6 months) 2 165 -0.65 (-1.12 to -0.17) 0.01 40%
Intervention lesser frequency or intensity with OST (B3 months) 1 40 0.66 (-0.72 to 2.03) 0.35 N/A
Intervention lesser frequency or intensity with OST (C9 months) 1 90 -0.60 (-1.17 to -0.03) 0.04 N/A
Sharing needles/syringes by control intervention and length of follow-up post-intervention
(overall)
13 2730 -0.43 (-0.69 to -0.18) 0.0003 68%
Sharing other injecting paraphernalia by control intervention and length of follow-up post-intervention
Subgroups
Education/information (4–6 months) 1 219 -0.42 (-0.98 to 0.14) 0.15 N/A
HIV testing and counselling (4–6 months) 1 557 -0.11 (-0.43 to 0.21) 0.51 N/A
HIV testing and counselling (C9 months) 2 588 -0.20 (-0.40 to 0.01) 0.06 0%
Intervention lesser frequency or intensity (B3 months) 1 100 -0.41 (-0.83 to 0.01) 0.05 N/A
Intervention lesser frequency or intensity (4–6 months) 2 902 -0.20 (-0.40 to -0.01) 0.04 0%
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Of the 32 interventions delivered in the RCTs, most
(n = 14) were delivered to individual participants
[17, 19, 20, 24, 26, 29, 31, 33, 37, 48, 51–54]; eight were
delivered to groups [18, 23, 32, 34, 38, 39, 41, 49] and two to
couples [35, 45]. The remaining eight trials delivered inter-
ventions in a combination of ways e.g. individual and couples
sessions[46]; individual and group sessions [18, 25, 43, 47, 50];
group and couples sessions [22] and one trial provided both
individual and structural level activities [30]. For interventions
with more than one session, retention or adherence to the
intervention ranged from 50% [17] to 95% [29] (further detail
provided in the Online Supplementary Table II).
Eight interventions incorporated peer mentoring from an
index participant to change the behaviours of other PWID
[18, 21, 23, 25, 38, 39, 41, 47, 49]. The majority of
interventions contained at least three sessions (n = 25) [18,
20–23, 25, 29–32, 34, 35, 37–39, 41, 43, 46–50, 52, 53],
four interventions contained two sessions [17, 24, 44, 51]
and three interventions one session [26, 33, 54].
On thewhole, interventionsweredelivered indrug treatment
settings including outpatient and hospital clinics
[20, 21, 31, 48–50]; methadone maintenance clinics [32, 43];
inpatient or residential detoxification units [17, 24, 54]; needle
and syringe exchanges [22, 37] or outreach [49] (settings not
mutually exclusive). In addition, the vast majority of studies
weredeliveredby clinic staff in the treatment setting as opposed
to researcher delivered (or not specified) (Table 1).
Outcomes
Various validated and other purposely developed instruments
were used to assess injecting behaviour in 32 trials
[17–26, 29–35, 37–39, 41, 43, 45–52, 54] and sexual behaviour
in 24 trials [17–26, 29–32, 34, 35, 38, 39, 43, 45, 47, 49, 50, 54].
Themost common reporting timeframe for outcomeswas in the
past 30 days(n = 19) [17, 18, 22–26, 29, 32–34,
43, 46, 48–52, 54], followed by the past 3 months (n = 10)
[23, 30, 32, 35, 38, 39, 41, 45, 47, 50] or 6 months (n = 3)
[21, 25, 53], past week (n = 2) [20, 37] or behaviour at the last
sexual encounter or injecting event (n = 1) [19] (answers not
mutually exclusive as three trials reported different reporting
timeframe for different outcomes) [23, 25, 50].
Results of Individual RCTs Not Included
in the Meta-analyses
Of the eight trials omitted from the meta-analyses, three
reported that psychosocial interventions showed greater
reductions in injecting risk behaviours than education/in-
formation, usual care or HIV testing and counselling
[26, 37, 45] and three reported that psychosocial inter-
ventions showed greater reductions in sexual risk beha-
viours than or HIV testing and counselling [32, 35, 45].T
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Table 3 Sexual risk behaviours by control intervention and length of follow-up post-intervention
Outcome N
studies
N
participants
Std. mean difference (IV to random to 95
CI)
p value for
effect
I2
(%)
Any sexual risk behaviours by control intervention and length of follow-up post-intervention
Subgroups
Education/information (B3 months) 1 145 -0.21 (-0.56 to 0.15) 0.25 N/A
Education/information (C9 months) 2 1078 -0.10 (-0.41 to 0.20) 0.51 60%
HIV testing and counselling (C9 months) 1 174 0.14 (-0.81 to 1.09) 0.77 N/A
Intervention lesser frequency or intensity without OST (B3 months) 2 180 -0.65 (-0.96 to -0.34) \0.0001 0%
Intervention lesser frequency or intensity without OST (4–6 months) 1 95 0.19 (-0.26 to 0.64) 0.41 N/A
Intervention lesser frequency or intensity without (OST C9 months) 1 966 0.01 (-0.24 to 0.25) 0.96 N/A
Intervention lesser frequency or intensity with OST (B3 months) 1 40 0.51 (-0.54 to 1.57) 0.34 N/A
Intervention lesser frequency or intensity with OST (C9 months) 1 90 -0.76 (-1.55 to 0.04) 0.06 N/A
Any sexual risk behaviours by control intervention and length of follow-up post-intervention
(overall)
10 2768 -0.19 (-0.39 to 0.01) 0.07 58%
Unprotected sex by control intervention and length of follow-up post-intervention
Subgroups
Education/information (C9 months) 1 851 0.03 (-0.18 to 0.24) 0.79 N/A
HIV testing and counselling (C9 months) 1 174 0.14 (-0.81 to 1.09) 0.77 N/A
Intervention lesser frequency or intensity without OST (B3 months) 180 -0.65 (-0.96 to -0.34) \0.0001 0%
Intervention lesser frequency or intensity without OST (4–6 months) 1 48 -0.61 (-1.19 to -0.02) 0.04 N/A
Intervention lesser frequency or intensity without OST (C9 months) 1 423 0.01 (-0.19 to 0.21) 0.94 N/A
Intervention lesser frequency or intensity with OST (B3 months) 1 40 0.51 (-0.54 to 1.57) 0.34 N/A
Intervention lesser frequency or intensity with OST (C9 months) 1 90 -0.60 (-1.17 to -0.03) 0.04 N/A
Unprotected sex by control intervention and length of follow-up post-intervention (overall) 8 1806 -0.27 (-0.54 to -0.01) 0.04 68%
Number of partners by control intervention and length of follow-up post-intervention
Subgroups
Education/information (C9 months) 1 227 0.01 (-0.14 to 0.17) 0.89 N/A
Intervention lesser frequency or intensity without OST (4–6 months) 1 48 3.24 (2.36 to 4.12) \0.00001 N/A
Number of Partners by control intervention and length of follow-up post-intervention (overall) 2 275 0.11 (-0.05 to 0.26) 0.17 98%
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Meta-analyses
Any Injecting Risk Behaviour
Twenty-two RCTs assessed any injecting risk behaviour
(Fig. 3a). Psychosocial interventions independently
reduced injecting risk behaviours more than control
interventions in seven trials [21, 22, 25, 38, 41, 46, 48]. A
total of 3096 and 2971 PWID were included in the inter-
vention and control groups respectively. Overall, psy-
chosocial interventions showed a greater reduction in any
injecting risk behaviour (SMD -0.29; 95% CI -0.42 to
-0.15; I2 = 61%; p =\0.01) than control interventions
(Fig. 3a). Psychosocial interventions also demonstrated
Ϯ Includes 6 trials listed in the clinical trials database for which no published papers could be found.
* Includes 4 related manuscripts referenced in potentially eligible manuscripts
Records idenfied from electronic 
database searches
(n = 2570)
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Records aer duplicates removed 
(n = 1903) 
Abstracts screened
(n = 1903)
Records excluded
(n =  1771)Ϯ
Full-text manuscripts 
assessed for eligibility 
(n = 132)*
Full-text manuscripts excluded
(n = 89)
• 34 not RCT
• 29 outcomes of interest not 
assessed/not presented 
• 10 did not compare intervenon 
condions/did not evaluate eﬀect 
of intervenon
• 6 results not reported by PWID
• 4 not conducted among PWID
• 4 intervenon not psychosocial 
• 1 both treatment groups received 
same psychosocial intervenon
• 1 manuscript published in Chinese
Manuscripts included          
in systemac review
(n = 43) Trials (n = 32)
Trials included                
in meta-analysis
(n = 24)
Records idenfied from other 
sources
(n = 1)
Fig. 1 Flowchart.  Includes 6 trials listed in the clinical trials database for which no published papers could be found. *Includes 4 related
manuscripts referenced in potentially eligible manuscripts
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greater reductions in any risk behaviours than education/
information (SMD -0.41; 95% CI -0.79 to -0.04;
I2 = 62%; p = 0.03); HIV testing and counselling (SMD
-0.24; 95% CI -0.44 to -0.03; I2 = 0%; p = 0.02);
interventions of a lesser time or intensity (SMD -0.34;
95% CI -0.56 to -0.12; I2 = 75%; p\ 0.01), but no
difference was found when compared with interventions of
a lesser time or intensity that included OST (SMD 0.23;
95% CI 0.51–0.97; I2 = 0%; p\ 0.01) or treatment as
usual (SMD -0.09; 95% CI -0.32 to 0.15; I2 = 26%;
p = 0.54). Where outcomes were assessed B3 or
4–6 months post-intervention, psychosocial interventions
reduced any injecting risk behaviour when compared with
interventions of lesser time or intensity. Where outcomes
were compared C9 months post-intervention, psychosocial
interventions reduced any injecting risk behaviour more
than interventions that provided education/information
alone (Table 2). Heterogeneity was moderate in psy-
chosocial interventions compared to education/information
(I2 = 62%), possibly due to the variations in the mode of
delivery and intervention components (Table 1). The edu-
cation/information interventions in the control conditions
included a pamphlet compared to a 6 session education/
enablement intervention [39] and ranged from comparing a
one-session education intervention with a one-session
motivational intervention [33], to comparing 22 education
sessions with referrals to drug treatment with a 22-week
intervention including motivational interviewing counsel-
ing sessions for both the male participant and the couple,
monetary incentives for drug abstinence, and research-
supported detoxification followed by naltrexone treatment
[46]. There was high heterogeneity in the analysis of psy-
chosocial interventions compared to interventions of a
lesser time or intensity (without OST) (I2 = 75%) for
similar reasons to those mentioned above. Six trials
included equal-attention control conditions ranging from 2
[24] to 10 [41] sessions, and three included control inter-
ventions with fewer sessions, ranging from four versus one
session [31] to ten versus eight sessions [47] (Table 1). All
but one trial [31] had at least two sessions in the control
and/or intervention conditions. One trial compared a two-
session woman focused intervention with a two-session
nutritional intervention [24]. The variation in intervention
duration and content across conditions contributes to the
high heterogeneity.
Sharing Needles and Syringes
Thirteen RCTs assessed sharing of needles/syringes
(Fig. 3b). Psychosocial interventions reduced this beha-
viour more than the control interventions in five of those
trials [21, 22, 43, 46, 48]. A total of 1411 and 1315 PWID
were included in the intervention and control groups
Fig. 2 Risk of bias for included trials
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respectively. Overall, psychosocial interventions reduced
the sharing of needle/syringes (SMD -0.43; 95% CI -0.69
to -0.18; I2 = 68%; p\ 0.01) compared with control
interventions. Psychosocial interventions reduced needle
and syringe sharing compared with education/information
(SMD -0.52; 95% CI -1.02 to -0.03; I2 = 10%;
p = 0.04); or HIV testing and counselling (SMD -0.24;
95% CI -0.44 to -0.03; I2 = 0%; p = 0.02); but no dif-
ference was found when compared with interventions of a
lesser time or intensity (SMD -0.56; 95% CI -0.12 to
0.09; I2 = 90%; p = 0.09), interventions of a lesser time
or intensity that included OST (SMD -0.13; 95% CI
-1.32,1.05; I2 = 63%; p = 0.83) or treatment as usual
(SMD -0.53; 95% CI -1.12 to 0.07; p = 0.08; one trial).
Where outcomes were assessed B3 or 4–6 months post-
intervention, psychosocial interventions reduced needle
and syringe sharing more than interventions of lesser time
or intensity. Where outcomes were assessed 4–6 months
post-intervention, a greater reduction in any injecting risk
behaviour was found for psychosocial interventions com-
pared with HIV testing and counselling (Table 2). There
was moderate and high heterogeneity in the analysis of
psychosocial interventions compared to interventions of a
lesser time or intensity with (I2 = 63%) and without OST
(I2 = 90%), again potentially explained by the differences
in intervention content and delivery. The two trials that
compared psychosocial interventions with OST to inter-
ventions of a lesser time/intensity with OST varied in
length of OST treatment. Both included a 12-week psy-
chosocial intervention, however, the trial where methadone
was prescribed for six months independently reduced
needle and syringe sharing [43] and the trial that prescribed
methadone for three months did not [20]. Four trials
compared psychosocial interventions with interventions of
a lesser time or intensity without OST, two delivered to
couples [22] or encouraged peer outreach [21] indepen-
dently reduced needle and syringe sharing, whereas those
delivered to individuals on their own or in groups did not
[29, 50].
Sharing Other Injecting Paraphernalia
SevenRCTs assessed sharingof injectingparaphernalia (other
than needles/syringes) (Fig. 3c). None independently found
the psychosocial intervention to be more efficacious than the
control interventions. A total of 1209 and 1157 PWID were
included in the intervention and control groups respectively.
Overall, psychosocial interventions showed greater reduc-
tions in the sharing of other injecting paraphernalia (SMD
-0.21; 95% CI -0.34 to -0.09; I2 = 0%; p\ 0.01) com-
pared with control interventions. Psychosocial interventions
reduced the sharing of other injecting paraphernaliamore than
interventions of a lesser time or intensity without OST (SMD
-0.24; 95% CI -0.42 to -0.06; I2 = 0%; p\ 0.01); but no
differences were found when compared with education/in-
formation (SMD-0.42; 95%CI-0.98 to 0.14; p = 0.15; one
trial); and HIV testing and counselling (SMD-0.17; 95% CI
-0.34 to 0.00; I2 = 0%; p = 0.05). Where outcomes were
compared 4–6 months post-intervention, psychosocial inter-
ventions significantly reduced sharing of other injecting
paraphernalia compared with interventions of lesser time or
intensity (Table 2).
Injecting Frequency
Eight RCTs assessed frequency of injecting (Fig. 3d).
Psychosocial interventions independently reduced fre-
quency of injecting compared with the control interven-
tions in four trials [29, 46, 48, 49]. A total of 1168 and
1177 PWID were included in the intervention and control
groups respectively. Overall, psychosocial interventions
showed no difference in reducing frequency of injecting
(SMD -0.17; 95% CI -0.35 to 0.00; I2 = 61%;
p = 0.05). Psychosocial interventions significantly reduced
the frequency of injecting compared with education/infor-
mation (SMD -1.05; 95% CI -2.07 to -0.03; p = 0.04;
one trial); but no difference was found when compared
with interventions of a lesser time or intensity with (SMD
0.09; 95% CI -0.61 to 0.79; I2 = 76%; p = 0.20; one
trial) and without OST (SMD -0.46; 95% CI -1.02 to
0.21; I2 = 66%; p = 0.80); HIV testing and counselling
(SMD -0.16; 95% CI -0.40 to 0.08; I2 = 76%; p = 0.20)
and treatment as usual (SMD -0.00; 95% CI -0.20 to
0.21; p = 0.96; one trial). Where outcomes were compared
4–6 months post-intervention, the frequency of injecting
significantly reduced for participants receiving psychoso-
cial interventions compared with participants receiving
education/information (Table 2). There was moderate to
high heterogeneity in the analysis comparing psychosocial
interventions to HIV testing and counselling (I2 = 76%)
and to interventions of a lesser time/intensity with
(I2 = 66%) and without OST (I2 = 66%), again potentially
explained by the differences in intervention content and
delivery described above. All HIV testing and counselling
intervention control groups received two sessions com-
pared to the intervention conditions that ranged from seven
[49] to ten sessions [18] in comparison.
bFig. 3 Efficacy of psychosocial interventions versus control inter-
ventions in reducing a ANY injecting risk behaviours among people
who inject drugs, b sharing of needles or syringes among people who
inject drugs, c sharing of other injecting equipment (not needle/
syringes) among people who inject drugs, d frequency of injecting
among people who inject drugs
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Any Sexual Risk Behaviour
Ten RCTs assessed any sexual risk behaviour (Fig. 4a).
Psychosocial interventions were independently more likely
to reduce any sexual risk behaviour than the control
interventions in two trials [22, 24]. A total of 1359 and
1409 PWID were included in the intervention and control
groups respectively. Overall, psychosocial interventions
reduced any sexual risk behaviour compared with control
interventions (SMD -0.19; 95% CI -0.39, 0.01;
I2 = 58%; p = 0.07). Psychosocial interventions showed
no difference in reducing any sexual risk behaviours
compared with education/information (SMD -0.12; 95%
CI -0.32 to 0.09; I2 = 34%; p = 0.27), interventions of a
lesser time or intensity with (SMD -0.26; 95% CI -0.67
to 0.15; I2 = 78%; p = 0.21); and without OST (SMD
-0.17; 95% CI -1.41,1.07; I2 = 72%; p = 0.79); and
HIV testing and counselling (SMD 0.14; 95% CI
-0.81,1.09; p = 0.77; one trial). Where outcomes were
compared B3 months post-intervention, psychosocial
interventions reduced any sexual risk behaviour compared
with interventions of a lesser time or intensity (without
OST) (Table 3). The high heterogeneity in the analysis
comparing psychosocial interventions to interventions of a
lesser time or intensity with (I2 = 78%) and without OST
(I2 = 72%) has already been discussed.
Fig. 3 continued
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Unprotected Sex
Eight RCTs assessed unprotected sex (Fig. 4b). Psy-
chosocial interventions were independently more effective
than the control interventions in four trials [22, 24, 29, 43].
A total of 876 and 930 PWID were included in the inter-
vention and control groups respectively. Overall, psy-
chosocial interventions reduced unprotected sex more than
control interventions (SMD -0.27; 95% CI -0.54 to
-0.01; I2 = 68%; p = 0.04). Psychosocial interventions
reduced unprotected sex compared with interventions of a
lesser time or intensity (without OST) (SMD -0.44; 95%
CI -0.86 to -0.01; I2 = 79%; p = 0.04); but no differ-
ence was reported when compared with education/infor-
mation (SMD 0.03; 95% CI -0.18 to 0.24; p = 0.79; one
trial), interventions of a lesser time or intensity with OST
(SMD -0.13; 95% CI -1.21 to 0.94; I2 = 70%;
p = 0.81); and HIV testing and counselling (SMD 0.14;
95% CI -0.81,1.09; p = 0.77; one trial). Where outcomes
were compared B3 and 4–6 months post-intervention,
psychosocial interventions reduced unprotected sex com-
pared to interventions of a lesser time or intensity (without
OST). Where outcomes were assessed C9 months post-
intervention, psychosocial interventions reduced unpro-
tected sex compared with interventions of a lesser time or
intensity (with OST) (Table 3).
Number of Sexual Partners
Two RCTs assessed number of sexual partners (Fig. 4c). A
total of 135 and 140 PWID were included in the inter-
vention and control groups respectively. There was no
difference between psychosocial interventions and educa-
tion/information in reducing the number of sexual partners
(SMD 0.01; 95% CI -0.14 to 0.17; one trial). Interventions
of a lesser time or intensity (without OST) reduced the
number of sexual partners compared with psychosocial
interventions (SMD 3.24; 95% CI 2.36,4.12; one trial).
Discussion
The aim of the review and meta-analysis was to identify
and evaluate the impact of psychosocial interventions
designed to reduce injecting risk and sexual risk behaviours
among PWID. A total of 24 trials were included in the
meta-analysis. Overall, psychosocial interventions reduced
some of the target injecting (sharing of needle and syringes
and other injecting paraphernalia) and sexual risk beha-
viour (unprotected sex) outcomes among PWID when
compared with control conditions. More specifically, the
meta-analysis found that psychosocial interventions
reduced the sharing of needles and syringes compared to
education/information or HIV testing and counselling,
reduced the sharing of other injecting paraphernalia com-
pared to interventions of a lesser time or intensity, reduced
the frequency of injecting compared to one trial of edu-
cation/information, and reduced unprotected sex compared
to interventions of a lesser time or intensity. Although
psychosocial interventions targeted injecting risk beha-
viours rather than a reduction in injecting behaviour per se,
one trial reported a significant effect (p = 0.05) with
regards to reduced frequency of injecting. Psychosocial
interventions were no more likely than control interven-
tions to reduce the number of sexual partners. However,
only two trials were pooled in this specific meta-analysis,
and many participants reported being in a steady relation-
ship. Interestingly, they also reported a reduction in
unprotected sex, a factor which may be more important in
reducing BBV transmission than the number of sex part-
ners [25, 29].
Using data on outcomes collected at nine-months or
more post-intervention, the meta-analyses found psy-
chosocial interventions produced more reported behaviour
change than control interventions, suggesting that mainte-
nance or booster sessions may be required to sustain pos-
itive behaviour change.
One study found stronger intervention effects for those
who had known their HCV-positive status for at least six
months, but not for those who had known their HCV-
positive status for more than 12 months [41], suggesting a
window of opportunity may exist following HCV diagnosis
to address transmission risks.
Overall and regardless of intervention or control con-
tent, 16 of the 32 trials included in the systematic review
reported greater reductions in injecting or sexual risk
behaviours in participants in the intervention group com-
pared to the control group
[21, 22, 24–26, 29, 32, 35, 37, 38, 41, 43, 45, 46, 48, 49].
Only two trials in the review (with small sample sizes)
included contingency management (incentivisation). One
of these trials reported greater reductions in injecting risk
behaviours in the intervention group (22 sessions of
motivational interviewing for the male participant and
couple (female partner drug-free) plus contingency man-
agement and naltrexone) compared to the control group (22
sessions of education, including referrals to a detoxification
programme and aftercare that may or may not have
included naltrexone) [46]. The other reported no significant
difference in injecting or sexual risk behaviours between
the intervention (29 week intervention including 12 weeks
bFig. 4 Efficacy of psychosocial interventions versus control inter-
ventions in reducing a ANY sexual risk behaviours among people
who inject drugs, b unprotected sex among people who inject drugs,
c number of sexual partners among people who inject drugs
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of CBT and contingent vouchers (as well as standard care:
methadone ? 5 weekly individual counselling, followed
by 12 weeks standard treatment) and control groups
(29 week standard care intervention (same as intervention
group) including 12 weeks of group therapy and non-
contingent vouchers) [20] (Table 1). Only three of the
seven trials [18, 19, 26, 33, 37, 43, 53] of psychosocial
interventions including motivational interviewing found
greater reductions in some injecting and sexual risk beha-
viours [26, 37, 43]. As these three interventions varied in
content and participant group (e.g. one session interactive
session for female sex workers [26]; computerised inter-
vention (69% male) [37]; and PWID entering OST (70%
male) [43]; results about the effectiveness of specific
intervention functions (e.g. incentivisation or persuasion)
in reducing BBV risk behaviours among PWID are
inconclusive.
Limitations
Limitations include the low number of studies for inclusion
in some of the sub-group analyses of behavioural outcomes
and intervention delivery modes. In addition, there was
heterogeneity in terms of the interventions studied and their
duration, as well as differences in sample sizes and char-
acteristics, length of follow-up, and assessment methods
used to determine risk behaviours. This lack of consistency
across studies may have contributed to the moderate levels
of heterogeneity noted in the meta-analyses. The most
common risk of bias in included RCTs was selective out-
come reporting and possible cross-over contamination
between groups. A further limitation is that authors of the
eight trials not included in the meta-analysis were not
contacted to determine whether they could supply the
additional data required to include the trial in the meta-
analysis. It is acknowledged that this could have resulted in
a potential source of bias in the findings. These limitations
need to be considered when interpreting the results.
Conclusions
Whilst indications from the meta-analysis suggest that
psychosocial interventions (when compared to control)
reduce risk taking behaviour outcomes, more research is
needed. The findings highlight the difficulty and com-
plexity involved in attempting to examine the effectiveness
of interventions that include different content and func-
tions, modes of delivery, dosage and number of sessions.
This heterogeneity in both the control and intervention
conditions resulted in challenges to fully interpret the
findings. It will be important to determine what types of
psychosocial interventions work for whom and in what
settings [8]. Our findings suggest that psychosocial inter-
ventions could boost the impact of current harm reduction
interventions delivered as routine care and could be
included with other harm reduction approaches, including
OST and needle and syringe exchange, to reduce BBV
transmission risks among PWID. Further trials should
address some of the limitations in terms of target popula-
tions, dose and frequency and timing of outcome measures.
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